MCID: GLC086
MIFTS: 42

Glucocorticoid-Induced Osteoporosis

Categories: Bone diseases

Aliases & Classifications for Glucocorticoid-Induced Osteoporosis

MalaCards integrated aliases for Glucocorticoid-Induced Osteoporosis:

Name: Glucocorticoid-Induced Osteoporosis 12 15
Steroid-Induced Osteoporosis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0060343

Summaries for Glucocorticoid-Induced Osteoporosis

Disease Ontology : 12 An osteoporosis caused by chronic glucocorticoid use. Glucocorticoids impair the replication, differentiation and function of osteoblasts and induce the apoptosis of mature osteoblasts and osteocytes; the also favor osteoclastogenesis leading to an increase in bone resorption.

MalaCards based summary : Glucocorticoid-Induced Osteoporosis, also known as steroid-induced osteoporosis, is related to periodontitis and osteonecrosis. An important gene associated with Glucocorticoid-Induced Osteoporosis is BGLAP (Bone Gamma-Carboxyglutamate Protein), and among its related pathways/superpathways are Wnt Signaling Pathways: beta-Catenin-dependent Wnt Signaling and Osteoclast differentiation. The drugs Denosumab and Etidronic acid have been mentioned in the context of this disorder. Affiliated tissues include bone and testes, and related phenotypes are craniofacial and growth/size/body region

Wikipedia : 76 Steroid-induced osteoporosis (SIOP) is osteoporosis arising due to use of glucocorticoids (steroid... more...

Related Diseases for Glucocorticoid-Induced Osteoporosis

Diseases related to Glucocorticoid-Induced Osteoporosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 95)
# Related Disease Score Top Affiliating Genes
1 periodontitis 29.5 BGLAP RUNX2 TNFRSF11B TNFSF11
2 osteonecrosis 26.0 ACP5 BGLAP BMP2 PTH RUNX2 TNFRSF11B
3 osteoporosis 24.8 ACP5 BGLAP BMP2 CALCA DKK1 IGF1
4 nontoxic goiter 10.7 BGLAP CALCA
5 osteopetrosis, autosomal dominant 2 10.7 BGLAP TNFSF11
6 polyarticular onset juvenile idiopathic arthritis 10.7 TNFRSF11B TNFSF11
7 hemophilic arthropathy 10.6 TNFRSF11B TNFSF11
8 aneurysmal bone cysts 10.6 CALCA TNFSF11
9 multicentric reticulohistiocytosis 10.6 TNFRSF11B TNFSF11
10 periodontitis, chronic 10.6 TNFRSF11B TNFSF11
11 chronic apical periodontitis 10.6 TNFRSF11B TNFSF11
12 familial expansile osteolysis 10.6 TNFRSF11B TNFSF11
13 axial osteomalacia 10.5 BGLAP PTH
14 extraskeletal chondroma 10.5 BGLAP PTH
15 hypercalcemia, infantile, 1 10.5 CALCA PTH
16 impaired renal function disease 10.5 BGLAP PTH
17 cloacogenic carcinoma 10.4 CALCA PTH
18 joint disorders 10.4 DKK1 TNFSF11
19 alveolar periostitis 10.4 BGLAP RUNX2
20 idiopathic hypercalciuria 10.4 BGLAP TNFSF11
21 pseudohypoparathyroidism, type ib 10.4 BGLAP PTH
22 jaw cancer 10.4 PTH TNFSF11
23 metaphyseal chondrodysplasia, jansen type 10.4 CALCA PTH
24 carcinoid syndrome 10.4 CALCA IGF1
25 paget disease of bone 5, juvenile-onset 10.4 CALCA TNFRSF11B TNFSF11
26 bone giant cell tumor 10.3 ACP5 CALCA
27 villonodular synovitis 10.3 ACP5 TNFSF11
28 kummell's disease 10.3 DKK1 TNFRSF11B TNFSF11
29 trichorhinophalangeal syndrome, type i 10.3 RUNX2 TNFRSF11B
30 osteitis fibrosa 10.3 BGLAP CALCA PTH
31 hypophosphatasia, adult 10.2 BGLAP CALCA PTH
32 fibrogenesis imperfecta ossium 10.2 CALCA PTH TNFRSF11B
33 multiple endocrine neoplasia, type iia 10.2 CALCA PTH
34 parathyroid gland disease 10.2 BGLAP CALCA PTH
35 camurati-engelmann disease 10.2 ACP5 BGLAP
36 parathyroid adenoma 10.2 BGLAP CALCA PTH
37 primary hyperparathyroidism 10.2 BGLAP CALCA PTH
38 pigmented villonodular synovitis 10.2 ACP5 TNFSF11
39 arthritis 10.2
40 fibrous dysplasia 10.2 BGLAP CALCA IGF1
41 rheumatoid arthritis 10.1
42 rheumatic disease 10.1
43 enthesopathy 10.1
44 osteogenesis imperfecta, type i 10.1 BGLAP IGF1 TNFRSF11B
45 mineral metabolism disease 10.1 CALCA PTH
46 teeth hard tissue disease 10.1 ACP5 TNFSF11
47 hajdu-cheney syndrome 10.0 RUNX2 TNFSF11
48 cleidocranial dysplasia 10.0 BGLAP RUNX2
49 tooth ankylosis 10.0 BMP2 TNFSF11
50 giant cell tumor 10.0 BGLAP CALCA TNFRSF11B TNFSF11

Graphical network of the top 20 diseases related to Glucocorticoid-Induced Osteoporosis:



Diseases related to Glucocorticoid-Induced Osteoporosis

Symptoms & Phenotypes for Glucocorticoid-Induced Osteoporosis

MGI Mouse Phenotypes related to Glucocorticoid-Induced Osteoporosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 craniofacial MP:0005382 9.87 BMP2 DKK1 PTH RUNX2 SFRP1 TNFRSF11B
2 growth/size/body region MP:0005378 9.86 BMP2 DKK1 IGF1 PTH RUNX2 SFRP1
3 hematopoietic system MP:0005397 9.7 BMP2 IGF1 PTH RUNX2 SFRP1 TNFRSF11B
4 limbs/digits/tail MP:0005371 9.56 BMP2 DKK1 IGF1 PTH RUNX2 SFRP1
5 skeleton MP:0005390 9.23 DKK1 IGF1 PTH RUNX2 SFRP1 TNFRSF11B

Drugs & Therapeutics for Glucocorticoid-Induced Osteoporosis

Drugs for Glucocorticoid-Induced Osteoporosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 54)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Denosumab Approved Phase 4,Phase 3,Phase 1,Phase 2 615258-40-7
2
Etidronic acid Approved Phase 4,Phase 3 7414-83-7, 2809-21-4 3305
3
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
4
Teriparatide Approved, Investigational Phase 4,Phase 3,Phase 2 52232-67-4 16133850
5
Alendronate Approved Phase 4,Phase 3,Phase 2 121268-17-5, 66376-36-1 2088
6 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Calcium, Dietary Phase 4,Phase 3,Phase 2,Not Applicable
12 Diphosphonates Phase 4
13 Ibandronic acid Phase 4
14 calcium channel blockers Phase 4,Phase 3
15 Risedronate Sodium Phase 4,Phase 3 115436-72-1
16
Alfacalcidol Approved, Nutraceutical Phase 3,Not Applicable 41294-56-8 5282181
17
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 1406-16-2
18
Vitamin D3 Approved, Nutraceutical Phase 2, Phase 3,Phase 3 67-97-0 6221 5280795
19
Genistein Investigational Phase 2, Phase 3 446-72-0 5280961
20 Hydroxycholecalciferols Phase 3,Not Applicable
21 Micronutrients Phase 3,Phase 2,Not Applicable
22 Trace Elements Phase 3,Phase 2,Not Applicable
23 Vitamins Phase 3,Phase 2,Not Applicable
24 Estrogens Phase 2, Phase 3,Not Applicable
25 Phytoestrogens Phase 2, Phase 3
26 Protective Agents Phase 2, Phase 3
27 Protein Kinase Inhibitors Phase 2, Phase 3
28 Calciferol Nutraceutical Phase 2, Phase 3
29
Methylprednisolone Approved, Vet_approved 83-43-2 6741
30
Prednisolone Approved, Vet_approved 50-24-8 5755
31
Morphine Approved, Investigational 57-27-2 5288826
32
Tramadol Approved, Investigational 27203-92-5 33741
33
Calcitriol Approved, Nutraceutical Not Applicable 32222-06-3 134070 5280453
34 Vasoconstrictor Agents Not Applicable
35 Antiemetics
36 Anti-Inflammatory Agents
37 Autonomic Agents
38 Gastrointestinal Agents
39 Methylprednisolone acetate
40 Methylprednisolone Hemisuccinate
41 Neuroprotective Agents
42 Peripheral Nervous System Agents
43 Prednisolone acetate
44 Prednisolone hemisuccinate
45 Prednisolone phosphate
46 Estrogen Antagonists Not Applicable
47 Estrogen Receptor Modulators Not Applicable
48 Raloxifene Hydrochloride Not Applicable
49 Selective Estrogen Receptor Modulators Not Applicable
50 Analgesics

Interventional clinical trials:

(show all 21)
# Name Status NCT ID Phase Drugs
1 A Study of Once Monthly Bonviva (Ibandronate) in Prevention of Glucocorticoid-Induced Osteoporosis. Completed NCT00545051 Phase 4 Placebo;ibandronate
2 Denosumab in Current Users of Bisphosphonates for Glucocorticoid-induced Osteoporosis Completed NCT01465568 Phase 4 Denosumab;bisphosphonates
3 Efficacy of Monthly Ibandronate in Women With RA and Reduced Bone Mineral Density Receiving Long-term Steroids Completed NCT01287533 Phase 4 Ibandronate;Placebo
4 Risedronate and Parathyroid Hormone to Reverse Osteoporosis Caused by Chronic Steroid Use Completed NCT00221299 Phase 4 Risedronate;Parathyroid Hormone
5 HRT Versus Etidronate for Osteoporosis and Fractures in Asthmatics Receiving Glucocorticoids. Completed NCT00376662 Phase 4 Hormone Replacement Therapy and Etidronate
6 Denosumab Versus Bisphosphonates (Alendronate) in GIOP Recruiting NCT03005678 Phase 4 Denosumab;Alendronate
7 Zoledronic Acid in Cystic Fibrosis Withdrawn NCT01702415 Phase 4 Zoledronic acid;Placebo
8 Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol. Completed NCT00138983 Phase 3 Alendronate versus alfacalcidol (1-alpha OH vitamin D)
9 Comparison of the Effects of 2 Drugs on Lumbar Spine Volumetric BMD in Men With Glucocorticoid-Induced Osteoporosis Completed NCT00503399 Phase 3 Teriparatide;Risedronate
10 Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis Completed NCT00051558 Phase 3 Teriparatide;Alendronate Sodium;Placebo;Placebo
11 Safety and Efficiency of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis Recruiting NCT03164928 Phase 3 Denosumab
12 Effects of Genistein Aglycone in Glucocorticoid Induced Osteoporosis Recruiting NCT03040531 Phase 2, Phase 3 Alendronate Oral Tablet
13 Can Parathyroid Hormone Injections Reverse Glucocorticoid-induced Osteoporosis Completed NCT00004993 Phase 2 Parathyroid hormone (hPTH 1-34)
14 Forteo Trial on Idiopathic Osteoporosis in Premenopausal Women Active, not recruiting NCT01440803 Phase 2 Teriparatide;Saline Placebo
15 Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders Not yet recruiting NCT02418273 Phase 1, Phase 2 denosumab
16 Eldecalcitol for GLucocorticoid Induced OsteopoRosIs Versus Alfacalcidol Unknown status NCT01974167 Not Applicable Eldecalcitol;Alfacalcidol
17 GIOP Prevention Among People With Rheumatoid Arthritis Completed NCT00609830 Not Applicable
18 Glucocorticoid-induced Osteoporosis in Patients With Chronic Inflammatory Rheumatic Diseases or Psoriasis Recruiting NCT02719314 Glucocorticoid treatment
19 Study of the Diagnostic Value of Stable Calcium Isotope Profiling in Bone and Calcium Disorders Recruiting NCT02252679
20 Clinical Trial on the Efficacy of Raloxifene on Disease Activity in Rheumatoid Arthritis Not yet recruiting NCT02982083 Not Applicable Raloxifene hydrochloride;Placebo Oral Tablet
21 Percutaneous Vertebroplasty Versus Conservative Treatment in GIOPVCF Not yet recruiting NCT03330340

Search NIH Clinical Center for Glucocorticoid-Induced Osteoporosis

Genetic Tests for Glucocorticoid-Induced Osteoporosis

Anatomical Context for Glucocorticoid-Induced Osteoporosis

MalaCards organs/tissues related to Glucocorticoid-Induced Osteoporosis:

41
Bone, Testes

Publications for Glucocorticoid-Induced Osteoporosis

Articles related to Glucocorticoid-Induced Osteoporosis:

(show top 50) (show all 160)
# Title Authors Year
1
Effects of quality indicator monitoring for glucocorticoid-induced osteoporosis and trends of drug treatment in a Japanese hospital. ( 29878618 )
2018
2
Effects of the Phosphodiesterase-5 (PDE-5) Inhibitors, Avanafil and Zaprinast, on Bone Remodeling and Oxidative Damage in a Rat Model of Glucocorticoid-Induced Osteoporosis. ( 29557941 )
2018
3
Significant improvement of bone mineral density by denosumab without bisphosphonate pre-treatment in glucocorticoid-induced osteoporosis. ( 29251033 )
2018
4
Myricetin ameliorates glucocorticoid-induced osteoporosis through the ERK signaling pathway. ( 29883721 )
2018
5
Patient satisfaction and efficacy of switching from weekly bisphosphonates to monthly minodronate for treatment and prevention of glucocorticoid-induced osteoporosis in Japanese patients with systemic rheumatic diseases: a randomized, clinical trial. ( 29904824 )
2018
6
Gastrodin alleviates glucocorticoid induced osteoporosis in rats via activating the Nrf2 signaling pathways. ( 29545917 )
2018
7
The effects of denosumab and alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease: A randomized, controlled trial. ( 29543887 )
2018
8
Glucocorticoid-Induced Osteoporosis: Management Challenges in Older Patients. ( 29941355 )
2018
9
Glucocorticoid-induced osteoporosis: an update. ( 29691807 )
2018
10
Preservation of type H vessels and osteoblasts by enhanced preosteoclast platelet-derived growth factor type BB attenuates glucocorticoid-induced osteoporosis in growing mice. ( 29800693 )
2018
11
Epigallocatechin-3-Gallate Ameliorates Glucocorticoid-Induced Osteoporosis of Rats <i>in Vivo</i> and <i>in Vitro</i>. ( 29867459 )
2018
12
Just the FRAX: Management ofA Glucocorticoid-Induced Osteoporosis. ( 29337149 )
2018
13
Autophagy as a target for glucocorticoid-induced osteoporosis therapy. ( 29427075 )
2018
14
Role of Teriparatide in Glucocorticoid-induced Osteoporosis through Regulating Cellular Reactive Oxygen Species. ( 29745033 )
2018
15
Intramembranous ossification and endochondral ossification are impaired differently between glucocorticoid-induced osteoporosis and estrogen deficiency-induced osteoporosis. ( 29497100 )
2018
16
Denosumab: a new treatment option for glucocorticoid-induced osteoporosis. ( 29631783 )
2018
17
Efficacy of Denosumab for Glucocorticoid-Induced Osteoporosis in an Adolescent Patient with Duchenne Muscular Dystrophy: A Case Report. ( 29642113 )
2018
18
Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. ( 29631782 )
2018
19
Prevention of Glucocorticoid-Induced Osteoporosis: Clinical audit to evaluate the implementation of National Osteoporosis Guideline Group 2017 guidelines in a primary care setting. ( 29729949 )
2018
20
Pro-inflammatory cytokines: cellular and molecular drug targets for glucocorticoid-induced-osteoporosis via osteocyte. ( 29618305 )
2018
21
Denosumab for glucocorticoid-induced osteoporosis. ( 29849116 )
2018
22
The Efficacy of Minodronate in the Treatment of Glucocorticoid-induced Osteoporosis. ( 29607978 )
2018
23
The osteoblast: Linking glucocorticoid-induced osteoporosis and hyperglycaemia? A post-hoc analysis of a randomised clinical trial. ( 29729427 )
2018
24
Adenosine Receptor Stimulation Improves Glucocorticoid-Induced Osteoporosis in a Rat Model. ( 28928654 )
2017
25
Adrenomedullin inhibits osteoclast differentiation through the suppression of receptor activator of nuclear factor-I_B ligand-induced nuclear factor-I_B activation in glucocorticoid-induced osteoporosis. ( 29067096 )
2017
26
Effects of glucocorticoid-induced osteoporosis on bone tissue of rats with experimental periodontitis. ( 28178585 )
2017
27
2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. ( 28585410 )
2017
28
Bone: Towards a better management of glucocorticoid-induced osteoporosis? ( 28855696 )
2017
29
Targeting osteoblastic casein kinase-2 interacting protein-1 to enhance Smad-dependent BMP signaling and reverse bone formation reduction in glucocorticoid-induced osteoporosis. ( 28128304 )
2017
30
Effects of 1,25-dihydroxyvitamin D3 on the local bone renin-angiotensin system in a murine model of glucocorticoid-induced osteoporosis. ( 28587403 )
2017
31
Comment on 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. ( 28941168 )
2017
32
Low Doses of Simvastatin Potentiate the Effect of Sodium Alendronate in Inhibiting Bone Resorption and Restore Microstructural and Mechanical Bone Properties in Glucocorticoid-Induced Osteoporosis. ( 28743325 )
2017
33
Glucocorticoid-induced Osteoporosis. ( 28989868 )
2017
34
2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. ( 28941179 )
2017
35
Prevalence and risk factors associated with glucocorticoid-induced osteoporosis in Chinese patients with rheumatoid arthritis. ( 28374332 )
2017
36
Corrigendum to &amp;quot;Utilization of Preventive Measures for Glucocorticoid-Induced Osteoporosis among Veterans with Inflammatory Bowel Disease&amp;quot;. ( 29075661 )
2017
37
The osteogenesis-promoting effects of alpha-lipoic acid against glucocorticoid-induced osteoporosis through the NOX4, NF-kappaB, JNK and PI3K/AKT pathways. ( 28611356 )
2017
38
Tetramethylpyrazine Protects Against Glucocorticoid-Induced Apoptosis by Promoting Autophagy in Mesenchymal Stem Cells and Improves Bone Mass in Glucocorticoid-Induced Osteoporosis Rats. ( 27917698 )
2017
39
Prevalence and incidence of osteoporotic fractures in patients on long-term glucocorticoid treatment for rheumatic diseases: the Glucocorticoid Induced OsTeoporosis TOol (GIOTTO) study. ( 28535619 )
2017
40
Advances in treatment of glucocorticoid-induced osteoporosis. ( 28857847 )
2017
41
Promotion effect of extracts from plastrum testudinis on alendronate against glucocorticoid-induced osteoporosis in rat spine. ( 28878388 )
2017
42
Caffeic acid phenethyl ester protects against glucocorticoid-induced osteoporosis in vivo: Impact on oxidative stress and RANKL/OPG signals. ( 28363435 )
2017
43
Icariin protects against glucocorticoid induced osteoporosis, increases the expression of the bone enhancer DEC1 and modulates the PI3K/Akt/GSK3I^/I^-catenin integrated signaling pathway. ( 28408345 )
2017
44
Preventive effects of<i>Polygonum multiflorum</i>on glucocorticoid-induced osteoporosis in rats. ( 28962180 )
2017
45
Effect of Time of Administration of Teriparatide on Bone Mineral Density in Glucocorticoid-Induced Osteoporosis. ( 28579148 )
2017
46
Evaluation of the anti-osteoporotic effect of Ginkgo biloba L. in Wistar rats with glucocorticoid-induced-osteoporosis by bone densitometry using dual-energy x-ray absorptiometry (DEXA) and mechanical testing. ( 29044313 )
2017
47
Silencing miR-106b accelerates osteogenesis of mesenchymal stem cells and rescues against glucocorticoid-induced osteoporosis by targeting BMP2. ( 28108317 )
2017
48
Alpinumisoflavone protects against glucocorticoid-induced osteoporosis through suppressing the apoptosis of osteoblastic and osteocytic cells. ( 29203387 )
2017
49
A Novel Hybrid Compound LLP2A-Ale Both Prevented and Rescued the Osteoporotic Phenotype in a Mouse Model of Glucocorticoid-Induced Osteoporosis. ( 27679514 )
2017
50
2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. ( 28585373 )
2017

Variations for Glucocorticoid-Induced Osteoporosis

Expression for Glucocorticoid-Induced Osteoporosis

Search GEO for disease gene expression data for Glucocorticoid-Induced Osteoporosis.

Pathways for Glucocorticoid-Induced Osteoporosis

GO Terms for Glucocorticoid-Induced Osteoporosis

Cellular components related to Glucocorticoid-Induced Osteoporosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 BGLAP BMP2 CALCA DKK1 IGF1 PTH
2 extracellular space GO:0005615 9.28 BGLAP BMP2 CALCA DKK1 IGF1 PTH

Biological processes related to Glucocorticoid-Induced Osteoporosis according to GeneCards Suite gene sharing:

(show all 37)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.96 BMP2 IGF1 RUNX2 SFRP1
2 negative regulation of transcription, DNA-templated GO:0045892 9.94 BMP2 CALCA RUNX2 SFRP1
3 positive regulation of gene expression GO:0010628 9.89 BMP2 DKK1 IGF1 RUNX2
4 response to drug GO:0042493 9.86 BGLAP PTH SFRP1 TNFRSF11B
5 negative regulation of canonical Wnt signaling pathway GO:0090090 9.81 BMP2 DKK1 SFRP1
6 response to nutrient levels GO:0031667 9.7 BGLAP IGF1 PTH
7 chondrocyte differentiation GO:0002062 9.67 BMP2 RUNX2
8 positive regulation of Wnt signaling pathway GO:0030177 9.67 BMP2 SFRP1
9 bone mineralization GO:0030282 9.67 BGLAP BMP2
10 positive regulation of osteoblast differentiation GO:0045669 9.67 BMP2 IGF1 RUNX2
11 osteoblast differentiation GO:0001649 9.67 BGLAP BMP2 RUNX2 SFRP1
12 positive regulation of bone mineralization GO:0030501 9.65 BMP2 PTH
13 positive regulation of glucose import GO:0046326 9.65 IGF1 PTH
14 ERK1 and ERK2 cascade GO:0070371 9.65 IGF1 TNFSF11
15 cellular response to growth factor stimulus GO:0071363 9.65 BGLAP BMP2 SFRP1
16 negative regulation of osteoclast differentiation GO:0045671 9.63 CALCA SFRP1
17 response to vitamin D GO:0033280 9.62 BGLAP PTH
18 osteoblast development GO:0002076 9.62 BGLAP RUNX2
19 regulation of osteoclast differentiation GO:0045670 9.61 BGLAP TNFSF11
20 positive regulation of glycogen biosynthetic process GO:0045725 9.61 IGF1 PTH
21 cellular response to BMP stimulus GO:0071773 9.61 BMP2 RUNX2 SFRP1
22 response to inorganic substance GO:0010035 9.6 BGLAP TNFRSF11B
23 negative regulation of bone resorption GO:0045779 9.58 CALCA TNFRSF11B
24 cellular response to vitamin D GO:0071305 9.58 BGLAP SFRP1
25 bone resorption GO:0045453 9.58 ACP5 PTH TNFSF11
26 positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus GO:1901522 9.57 BMP2 RUNX2
27 ossification GO:0001503 9.56 BGLAP BMP2 RUNX2 TNFSF11
28 negative regulation of cardiac muscle cell differentiation GO:2000726 9.55 BMP2 DKK1
29 regulation of odontogenesis of dentin-containing tooth GO:0042487 9.54 BMP2 RUNX2
30 bone mineralization involved in bone maturation GO:0035630 9.51 BMP2 IGF1
31 negative regulation of ossification GO:0030279 9.5 CALCA DKK1 SFRP1
32 regulation of signaling receptor activity GO:0010469 9.5 BMP2 CALCA DKK1 IGF1 PTH TNFRSF11B
33 Wnt signaling pathway involved in somitogenesis GO:0090244 9.46 DKK1 SFRP1
34 positive regulation of ossification GO:0045778 9.33 BMP2 CALCA PTH
35 skeletal system development GO:0001501 9.1 BGLAP BMP2 IGF1 PTH RUNX2 TNFRSF11B
36 multicellular organism development GO:0007275 10.06 BMP2 DKK1 SFRP1 TNFRSF11B TNFSF11
37 positive regulation of transcription by RNA polymerase II GO:0045944 10.04 BMP2 IGF1 PTH RUNX2 TNFSF11

Molecular functions related to Glucocorticoid-Induced Osteoporosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.43 BMP2 TNFRSF11B TNFSF11
2 growth factor activity GO:0008083 9.33 BMP2 DKK1 IGF1
3 co-receptor binding GO:0039706 8.96 BMP2 DKK1
4 hormone activity GO:0005179 8.8 CALCA IGF1 PTH

Sources for Glucocorticoid-Induced Osteoporosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....